REG - Creo Medical Group - Award of Shares under Share Incentive Plan

Creo MedicalAnnouncement

21/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250121:nRSU0052Ua&default-theme=true

RNS Number : 0052U  Creo Medical Group PLC  21 January 2025

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Award of Shares under Share Incentive Plan, Director Dealings, Issue of Equity
and TVR

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the
emerging field of minimally invasive surgical endoscopy for pre-cancer and
cancer patients, implemented an HMRC approved Share Incentive Plan ("SIP")
during 2020 which is available to all of the Company's UK based employees,
including Directors.

 

Under the SIP, shares are acquired in four ways:

·    Partnership Shares where an employee can spend up to a £1,800 or 10%
of their pre-tax income, whichever is the lower;

·    Matching Shares, where Creo can give up to two free Matching Shares
for each Partnership Share bought.  The plan requires employees to remain in
employment for three years to benefit from the Matching Shares;

·    Free Shares, where Creo can give up to £3,600 of free shares in any
tax year; and

·    Dividend Shares where additional shares can be bought with any
dividends paid.

 

The Company has been notified that Fiduchi Trustees (UK) Limited ("Fiduchi"),
the independent trustee of the SIP, acquired, in accordance with the SIP's
rules and on behalf of SIP participants, 248,132 ordinary shares in the
Company ("Ordinary Shares"), at a price of £0.191 per Ordinary Share on 16
January 2025 to meet its obligations under the SIP.  Under the terms of the
SIP, the Company is required to issue to the SIP, two Ordinary Shares in the
Company for each Partnership Share purchased (being 496,264 Ordinary Shares in
total).  Fiduchi holds 171,924 unallocated shares within the SIP (being
shares previously allocated to employees who ceased employment before the
shares had vested) which can be utilised to part satisfy the Company's
obligation. Accordingly, 324,340 new Ordinary Shares are required to be issued
by the Company to be held by Fiduchi as trustee of the SIP.

 

Craig Gulliford, Richard Rees and Christopher Hancock, executive directors of
the Company (the "Participating Directors") have received Partnership Shares
at a price of £0.191 per share and Matching Shares at a price of £0.001 per
share in accordance with terms of the SIP (the "Transaction"). Following this
the Participating Directors' shareholdings in the Company are as set out in
the table below:

 

 Director                  Total number of Ordinary Shares purchased or awarded under SIP  Total number of Ordinary Shares held post Transaction
 Craig Gulliford, CEO      14,136                                                          1,666,907(1)
 Richard Rees, CFO         14,136                                                          3,050,676(2)
 Christopher Hancock, CTO  14,136                                                          4,838,793

 

Accordingly, the Company announces that it has made an application for 324,340
new Ordinary Shares to be admitted to trading on AIM.  It is expected that
admission will take place on 28 January 2025.  Following the allotment and
issue, the Company's issued share capital consists of 412,473,319 Ordinary
Shares. The Company does not hold any shares in Treasury. As such the total
number of shares in issue with voting rights is 412,473,319.

 

Total Voting Rights (TVR)

 

The above figure of 412,473,319 may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the Company under
the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

The notifications below, made in accordance with the requirements of the
Market Abuse Regulation, provide further detail in relation to the award of
the SIP Shares to the Participating Directors.

 

Notes:

(1) Includes shares held by Mr Gulliford's wife.

(2) Includes shares held by Mr Rees's wife.

 

For further information please contact:

 

 Creo Medical Group plc                                                  www.creomedical.com
                                                                         (https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)
 Richard Craven, Company Secretary                                       Via Walbrook PR

 Cavendish Capital Markets Limited

 (Nominated Adviser and Joint Broker)                                    +44 (0)20 7220 0500
 Stephen Keys / Camilla Hume / George Lawson (NOMAD)
 Michael Johnson (Sales)

 Deutsche Numis (Joint Broker)                                           +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR Ltd                Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings  Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 Phillip Marriage               Mob: +44 (0)7867 984 082

 

 

 

About Creo Medical

 

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

 

 1. Details of PDMR
 a)  Name                                     Craig Gulliford
 b)  Position / status                        CEO
 c)  Initial notification / amendment         Initial notification
 2. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares
 b)  Nature of the transaction                Purchase of Ordinary Shares under Share Incentive Plan

 c)  Price(s) and volume(s)                   Prices   Volume(s)
                                              £0.191   4,712
 d)  Aggregated information                   N/A - Single transaction

     Aggregated volume Price
 e)  Date of the                              2025-01-16 GMT

     transaction
 f)  Place of the transaction                 London Stock Exchange

d)

Aggregated information

 

Aggregated volume Price

N/A - Single transaction

 

e)

Date of the

transaction

2025-01-16 GMT

f)

Place of the transaction

London Stock Exchange

 

 

 

 1. Details of PDMR
 a)  Name                                     Craig Gulliford
 b)  Position / status                        CEO
 c)  Initial notification / amendment         Initial notification
 2. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares
 b)  Nature of the transaction                Award of Ordinary Shares under Share Incentive Plan

 c)  Price(s) and volume(s)                   Prices   Volume(s)
                                              £0.001   9,424
 d)  Aggregated information                   N/A - Single transaction

     Aggregated volume Price
 e)  Date of the                              2025-01-20 GMT

     transaction
 f)  Place of the transaction                 London Stock Exchange

d)

Aggregated information

 

Aggregated volume Price

N/A - Single transaction

 

e)

Date of the

transaction

2025-01-20 GMT

f)

Place of the transaction

London Stock Exchange

 

 

 1. Details of PDMR
 a)  Name                                     Richard Rees
 b)  Position / status                        CFO
 c)  Initial notification / amendment         Initial notification
 2. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares
 b)  Nature of the transaction                Purchase of Ordinary Shares under Share Incentive Plan

 c)  Price(s) and volume(s)                   Prices   Volume(s)
                                              £0.191   4,712
 d)  Aggregated information                   N/A - Single transaction

     Aggregated volume Price
 e)  Date of the                              2025-01-16 GMT

     transaction
 f)  Place of the transaction                 London Stock Exchange

d)

Aggregated information

 

Aggregated volume Price

N/A - Single transaction

 

e)

Date of the

transaction

2025-01-16 GMT

f)

Place of the transaction

London Stock Exchange

 

 

 

 1. Details of PDMR
 a)  Name                                     Richard Rees
 b)  Position / status                        CFO
 c)  Initial notification / amendment         Initial notification
 2. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares
 b)  Nature of the transaction                Award of Ordinary Shares under Share Incentive Plan

 c)  Price(s) and volume(s)                   Prices   Volume(s)
                                              £0.001   9,424
 d)  Aggregated information                   N/A - Single transaction

     Aggregated volume Price
 e)  Date of the                              2025-01-20 GMT

     transaction
 f)  Place of the transaction                 London Stock Exchange

d)

Aggregated information

 

Aggregated volume Price

N/A - Single transaction

 

e)

Date of the

transaction

2025-01-20 GMT

f)

Place of the transaction

London Stock Exchange

 

 

 

 1. Details of PDMR
 a)  Name                                     Christopher Hancock
 b)  Position / status                        CTO
 c)  Initial notification / amendment         Initial notification
 2. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares
 b)  Nature of the transaction                Purchase of Ordinary Shares under Share Incentive Plan

 c)  Price(s) and volume(s)                   Prices   Volume(s)
                                              £0.191   4,712
 d)  Aggregated information                   N/A - Single transaction

     Aggregated volume Price
 e)  Date of the                              2025-01-20 GMT

     transaction
 f)  Place of the transaction                 London Stock Exchange

d)

Aggregated information

 

Aggregated volume Price

N/A - Single transaction

 

e)

Date of the

transaction

2025-01-20 GMT

f)

Place of the transaction

London Stock Exchange

 

 

 

 1. Details of PDMR
 a)  Name                                     Christopher Hancock
 b)  Position / status                        CTO
 c)  Initial notification / amendment         Initial notification
 2. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares
 b)  Nature of the transaction                Award of Ordinary Shares under Share Incentive Plan

 c)  Price(s) and volume(s)                   Prices   Volume(s)
                                              £0.001   9,424
 d)  Aggregated information                   N/A - Single transaction

     Aggregated volume Price
 e)  Date of the                              2025-01-20 GMT

     transaction
 f)  Place of the transaction                 London Stock Exchange

d)

Aggregated information

 

Aggregated volume Price

N/A - Single transaction

 

e)

Date of the

transaction

2025-01-20 GMT

f)

Place of the transaction

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBMMATMTJTBFA